CME Sessions at EANM’06

EANM’06 – CME Session II

October 1, 2006, 11:30 – 13:00
Critical review of diagnostic methods for assessment of dementia

Moderator: K. Tatsch (Munich)
Co-Moderator: A. Nordberg (Stockholm)

H. Hampel (Munich):
Role of biological markers and MR-based assessment in Alzheimer’s Diseases
P. Bartenstein (Mainz):
Critical Review of diagnostic methods for assessment of dementia: Role of FDG-PET
A. Nordberg (Stockholm):
Role of amyloid imaging

Educational objectives:

  1. Learn about the diagnostic role of biological markers in the differential diagnosis of neurodegenerative dementias.
  2. Describe the characteristic morphologic findings of dementias in MRI examinations.
  3. Discuss the role of FDG PET in the differential diagnosis of neurodegenerative dementias, including early detection, assessment of disease progression, and monitoring therapy.
  4. Analyze the potential role of nuclear medicine techniques directly targeting amyloid plaques.


This continuing education session is directed towards nuclear medicine physicians, radiologists and nuclear medicine technologists active in the performance and interpretation of neuroimaging studies in patients with dementias. It is designed to provide the participants a critical review on the role of current methods for diagnosing the most common types of dementias in daily clinical practice and in the research setting. The diagnostic contribution of biological CSF markers will be discussed along with the results provided by elaborate MRI techniques including morphometric analysis and spectroscopy. In addition, the role of functional PET imaging with FDG as an established, well accepted technique will be addressed based on a review of the literature and, in addition, covering the potential of refined analytical (pixelwise) approaches. Finally, the emerging role of imaging techniques directly targeting amyloid-plaques and neurofibrillary tangles will be summarized critically highlighting the future perspective of these approaches.

Key Words:

Neurodegenerative dementia, MRI, CSF markers, PET, glucose metabolism, amyloid plaque imaging

This website uses cookies. Learn more